20.47
-0.25(-1.21%)
Currency In USD
| Previous Close | 20.72 |
| Open | 20.34 |
| Day High | 20.66 |
| Day Low | 19.57 |
| 52-Week High | 22.73 |
| 52-Week Low | 8.58 |
| Volume | 1.11M |
| Average Volume | 2.54M |
| Market Cap | 1.77B |
| PE | -5.69 |
| EPS | -3.6 |
| Moving Average 50 Days | 18.93 |
| Moving Average 200 Days | 14.11 |
| Change | -0.25 |
If you invested $1000 in Syndax Pharmaceuticals, Inc. (SNDX) since IPO date, it would be worth $1,705.83 as of January 14, 2026 at a share price of $20.47. Whereas If you bought $1000 worth of Syndax Pharmaceuticals, Inc. (SNDX) shares 5 years ago, it would be worth $843.08 as of January 14, 2026 at a share price of $20.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
– Approximately $44 million and $125 million in preliminary (unaudited) Revuforj® (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increa
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 12:00 PM GMT
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will present at